Monroe Carell Jr. Children's Hospital at Vanderbilt

Summary

Monroe Carell Jr. Children's Hospital at Vanderbilt is a medical facility located in Nashville, Tennessee. This center is recognized for care of Acute Lymphoblastic Leukemia, Leukemia, Relapse, Premature Birth, Asthma and other specialties. Monroe Carell Jr. Children's Hospital at Vanderbilt is involved with conducting 159 clinical trials across 326 conditions. There are 20 research doctors associated with this hospital, such as Carrie Kitko, Devang J. Pastakia, Robert Naftel, MD, and Michael O'Connor, MD.

Top PIs

Clinical Trials running at Monroe Carell Jr. Children's Hospital at Vanderbilt

Asthma

Pulmonary Arterial Hypertension

Pneumonia

Heart Failure

Hydrocephalus

Rheumatoid Arthritis

Bronchiolitis

Cystic Fibrosis

Lazy Eye

Alagille Syndrome

Decision Support

for Lower Respiratory Infections in Children

Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.

Recruiting

1 award

N/A

2 criteria

Dupilumab

for Asthma

This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to \<6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A, all eligible participants will be offered participation in Part B, an optional open-label extension phase. Study details include: Part A: The study duration of part A will be up to 68 weeks consisting of a 4-week Screening, a 52week treatment period, and a 12-week post-treatment follow-up period. For participants who will chose to participate in Part B, the study duration will be up to 120 weeks (additional 52-week treatment period). Part B: For participants who will choose to participate in Part B, the study duration will be up to 120 weeks (Part A \[4-week Screening and a 52-week treatment period\] plus additional 52-week treatment period and a 12-week post-treatment follow-up period).

Recruiting

1 award

Phase 3

10 criteria

Montelukast

for Childhood Asthma

This trial is testing montelukast in children aged 4-12 with severe asthma attacks that don't respond well to standard treatments. Montelukast helps by blocking substances that cause airway inflammation, potentially improving breathing. The study aims to find the right dose that improves asthma symptoms.

Recruiting

0 awards

Phase 2

3 criteria